226 related articles for article (PubMed ID: 28323838)
1. Bupropion for the treatment of apathy in Huntington's disease: A multicenter, randomised, double-blind, placebo-controlled, prospective crossover trial.
Gelderblom H; Wüstenberg T; McLean T; Mütze L; Fischer W; Saft C; Hoffmann R; Süssmuth S; Schlattmann P; van Duijn E; Landwehrmeyer B; Priller J
PLoS One; 2017; 12(3):e0173872. PubMed ID: 28323838
[TBL] [Abstract][Full Text] [Related]
2. Bupropion for the Treatment of Apathy in Alzheimer Disease: A Randomized Clinical Trial.
Maier F; Spottke A; Bach JP; Bartels C; Buerger K; Dodel R; Fellgiebel A; Fliessbach K; Frölich L; Hausner L; Hellmich M; Klöppel S; Klostermann A; Kornhuber J; Laske C; Peters O; Priller J; Richter-Schmidinger T; Schneider A; Shah-Hosseini K; Teipel S; von Arnim CAF; Wiltfang J; Jessen F
JAMA Netw Open; 2020 May; 3(5):e206027. PubMed ID: 32463470
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 study.
Reilmann R; Anderson KE; Feigin A; Tabrizi SJ; Leavitt BR; Stout JC; Piccini P; Schubert R; Loupe P; Wickenberg A; Borowsky B; Rynkowski G; Volkinshtein R; Li T; Savola JM; Hayden M; Gordon MF;
Lancet Neurol; 2024 Mar; 23(3):243-255. PubMed ID: 38280392
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study.
Reilmann R; McGarry A; Grachev ID; Savola JM; Borowsky B; Eyal E; Gross N; Langbehn D; Schubert R; Wickenberg AT; Papapetropoulos S; Hayden M; Squitieri F; Kieburtz K; Landwehrmeyer GB; ;
Lancet Neurol; 2019 Feb; 18(2):165-176. PubMed ID: 30563778
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial.
Furr Stimming E; Claassen DO; Kayson E; Goldstein J; Mehanna R; Zhang H; Liang GS; Haubenberger D;
Lancet Neurol; 2023 Jun; 22(6):494-504. PubMed ID: 37210099
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trial.
Rosenberg PB; Lanctôt KL; Drye LT; Herrmann N; Scherer RW; Bachman DL; Mintzer JE; ADMET Investigators
J Clin Psychiatry; 2013 Aug; 74(8):810-6. PubMed ID: 24021498
[TBL] [Abstract][Full Text] [Related]
7. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies.
Clayton AH; Croft HA; Horrigan JP; Wightman DS; Krishen A; Richard NE; Modell JG
J Clin Psychiatry; 2006 May; 67(5):736-46. PubMed ID: 16841623
[TBL] [Abstract][Full Text] [Related]
8. Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study.
Jefferson JW; Rush AJ; Nelson JC; VanMeter SA; Krishen A; Hampton KD; Wightman DS; Modell JG
J Clin Psychiatry; 2006 Jun; 67(6):865-73. PubMed ID: 16848645
[TBL] [Abstract][Full Text] [Related]
9. Cholinesterase inhibitors for rarer dementias associated with neurological conditions.
Li Y; Hai S; Zhou Y; Dong BR
Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD009444. PubMed ID: 25734590
[TBL] [Abstract][Full Text] [Related]
10. Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial.
Huntington Study Group Reach2HD Investigators
Lancet Neurol; 2015 Jan; 14(1):39-47. PubMed ID: 25467848
[TBL] [Abstract][Full Text] [Related]
11. Bupropion sustained release added to group support for smoking cessation in schizophrenia: a new randomized trial and a meta-analysis.
Weiner E; Ball MP; Buchholz AS; Gold JM; Evins AE; McMahon RP; Buchanan RW
J Clin Psychiatry; 2012 Jan; 73(1):95-102. PubMed ID: 21535998
[TBL] [Abstract][Full Text] [Related]
12. A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients.
Reimherr FW; Cunningham LA; Batey SR; Johnston JA; Ascher JA
Clin Ther; 1998; 20(3):505-16. PubMed ID: 9663366
[TBL] [Abstract][Full Text] [Related]
13. Ethyl-eicosapentaenoic acid treatment in Huntington's disease: A placebo-controlled clinical trial.
Ferreira JJ; Rosser A; Craufurd D; Squitieri F; Mallard N; Landwehrmeyer B
Mov Disord; 2015 Sep; 30(10):1426-9. PubMed ID: 26175332
[TBL] [Abstract][Full Text] [Related]
14. Bupropion improved apathy in behavioral variant frontotemporal dementia: a case report.
Lin CP; Chu CP; Liu HC
Neurocase; 2016 Oct; 22(5):466-468. PubMed ID: 27484407
[TBL] [Abstract][Full Text] [Related]
15. Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial.
de Yebenes JG; Landwehrmeyer B; Squitieri F; Reilmann R; Rosser A; Barker RA; Saft C; Magnet MK; Sword A; Rembratt A; Tedroff J;
Lancet Neurol; 2011 Dec; 10(12):1049-57. PubMed ID: 22071279
[TBL] [Abstract][Full Text] [Related]
16. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
Hewett K; Chrzanowski W; Schmitz M; Savela A; Milanova V; Gee M; Krishen A; Millen L; Leary MO; Modell J
J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695
[TBL] [Abstract][Full Text] [Related]
17. Short-term continuous infusion of apomorphine hydrochloride for treatment of Huntington's chorea: A double blind, randomized cross-over trial.
Vitale C; Marconi S; Di Maio L; De Michele G; Longo K; Bonavita V; Barone P
Mov Disord; 2007 Dec; 22(16):2359-64. PubMed ID: 17894335
[TBL] [Abstract][Full Text] [Related]
18. Potential Role of Bupropion Sustained Release for Cancer-Related Fatigue: a Double-Blind, Placebo-Controlled Study.
Ashrafi F; Mousavi S; Karimi M
Asian Pac J Cancer Prev; 2018 Jun; 19(6):1547-1551. PubMed ID: 29936730
[TBL] [Abstract][Full Text] [Related]
19. A randomized, placebo-controlled trial of latrepirdine in Huntington disease.
Kieburtz K; McDermott MP; Voss TS; Corey-Bloom J; Deuel LM; Dorsey ER; Factor S; Geschwind MD; Hodgeman K; Kayson E; Noonberg S; Pourfar M; Rabinowitz K; Ravina B; Sanchez-Ramos J; Seely L; Walker F; Feigin A;
Arch Neurol; 2010 Feb; 67(2):154-60. PubMed ID: 20142523
[TBL] [Abstract][Full Text] [Related]
20. A randomised, placebo-controlled, double blind study of treatment of Huntington's disease with unsaturated fatty acids.
Vaddadi KS; Soosai E; Chiu E; Dingjan P
Neuroreport; 2002 Jan; 13(1):29-33. PubMed ID: 11924889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
